Zeqmelit® was launched in pharmacies in Sweden, Norway, and Finland in September 2024. The new order from Unimedic Pharma is part of AcuCort’s planned growth strategy and strengthens the company’s Nordic presence.

“The market launch in the Nordic region is progressing according to plan, and this order covers the initial phase of the launch in Denmark. It is gratifying that Zeqmelit® will soon also be available to Danish patients,” says AcuCort’s CEO, Jonas Jönmark.
 

The order value amounts to €18,500 and is expected to have a positive impact on AcuCort’s financial results.

For further information: 
Jonas Jönmark, vd, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.